EGM
RLAY icon

Engineers Gate Manager’s Relay Therapeutics RLAY Stock Holding History

Engineers Gate Manager’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-141,452
Closed -$1.41M – 2541
2026
Q1 		$1.41M Buy
141,452
+63,084
+80% +$564K 0.02% 880
2025
Q4 		$663K Buy
+78,368
New +$559K 0.01% 1230
2025
Q3 		– Sell
-38,719
Closed -$134K – 2467
2025
Q2 		$134K Buy
38,719
+9,281
+32% +$27.6K ﹤0.01% 1958
2025
Q1 		$77.1K Buy
+29,438
New +$115K ﹤0.01% 2023
2024
Q4 		– Sell
-50,351
Closed -$356K – 2521
2024
Q3 		$356K Buy
50,351
+2,051
+4% +$15.3K 0.01% 1547
2024
Q2 		$315K Sell
48,300
-1,074
-2% -$7.34K 0.01% 1442
2024
Q1 		$410K Buy
49,374
+22,260
+82% +$217K 0.01% 1303
2023
Q4 		$299K Sell
27,114
-31,237
-54% -$264K 0.01% 1452
2023
Q3 		$491K Buy
+58,351
New +$628K 0.02% 1073
2023
Q2 		– Sell
-17,397
Closed -$287K – 1982
2023
Q1 		$287K Sell
17,397
-17,688
-50% -$317K 0.01% 1264
2022
Q4 		$524K Buy
+35,085
New +$672K 0.03% 869

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Engineers Gate Manager's RLAY Position: Q2 2026 in Review

Engineers Gate Manager sold out of Relay Therapeutics (RLAY) in Q2 2026, closing a stake of 141,452 shares — an estimated $1.41M sold.

Engineers Gate Manager first reported a position in RLAY in Q4 2022 and held it in 11 quarters. The position peaked at $1.41M in Q1 2026. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Engineers Gate Manager reported no remaining Relay Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Engineers Gate Manager sold 141,452 Relay Therapeutics shares in Q2 2026, an estimated $1.41M.
  • Engineers Gate Manager first reported a position in Relay Therapeutics in Q4 2022 and held it in 11 quarters.
  • Engineers Gate Manager's Relay Therapeutics position peaked at $1.41M in Q1 2026.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.